Nevertheless, close monitoring of glucose status is advisable during GH treatment in a subset of AGHD patients with obesity or a family history of type 2 diabetes or both, because they are more prone to exhibit impaired glucose tolerance and diabetes mellitus in the first year of therapy20. Here, GH1 is linked to obesity due to melanocortin 4 receptor deficiency.